Complication of Transplanted Liver
5
0
0
3
Key Insights
Highlights
Success Rate
75% trial completion
Treatment Research
2 treatments under study, led by Quadravalent Human Papillomavirus Vaccine
Research Leaders
11 sponsors active, led by Northwestern Memorial Hospital
Related Conditions
Often studied with 6 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
20.0%
1 terminated out of 5 trials
75.0%
-11.6% vs benchmark
20%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (5)
Donor Specific HLA Alloantibodies in Liver Transplantation
Human Microbiota and Liver Transplant
Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients
Prediction of Hepatitis C Recurrence in Liver Transplant Recipients
Genetic Predisposition-Chronic Nephrotoxicity From CI-Liver Transplant Recipients-Potential Correlation-Urinary Biomarkers
Research Network
Common Treatments
- Quadravalent Human Papillomavirus Vaccine1
- Hlaalloantibodies Exposure1
Active Sponsors
- Northwestern Memorial Hospital2
- Northwestern University2
- Karolinska Institutet1
- The Hospital for Sick Children1
- The Physicians' Services Incorporated Foundation1
Top Investigators
Department of HPB Surgery and Transplants, Hospital Vall d´Hebron (Barcelona, Spain)
Northwestern Memorial Hospital
Department of Internal Medicine, Liver Unit, Hospital Vall d´Hebron (Barcelona, Spain)
The Hospital for Sick Chidren
Physiology and Pathophysiology of the Digestive Tract, Institut de Recerca Vall d´Hebron, Barcelona (Spain)
Related Conditions
- Hepatitis C Chronic1
- Acute Rejection Of Liver Transplant1
- Infection1
- Human Papillomavirusrelated Carcinoma1
- Late Complication From Kidney Transplant1